ALK Fusion

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma11
v::ALK Fusion	Crizotinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID1577 A phase-3 clinical trial evaluated 347 patients with ALK-positive lung cancer. The study compared crizotinib treatment (n=173) with chemotherapy treatment of either pemetrexed or docetaxel (n=174). … (full text at CIViC) PMID 26466010 · 2015 · Open in CIViC	civic
v::ALK Fusion	Alectinib + CrizotinibSubstitutes	Predictive	B	Supports Sensitivity Response	5	accepted	EID4858 In a randomized, open-label phase 3 trial 303 patients with ALK-positive, previously untreated NSCLC (including asympt. CNS disease) were randomized to reiceive either Alectinib or Crizotinib. During … (full text at CIViC) PMID 28586279 · Peters et al., 2017 ·

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Lung Non-Small Cell Carcinoma11

v::ALK Fusion

Crizotinib

Predictive

Supports Sensitivity Response

accepted

EID1577

A phase-3 clinical trial evaluated 347 patients with ALK-positive lung cancer. The study compared crizotinib treatment (n=173) with chemotherapy treatment of either pemetrexed or docetaxel (n=174). … (full text at CIViC)

PMID 26466010 · 2015 · Open in CIViC

civic

v::ALK Fusion

Alectinib + CrizotinibSubstitutes

Predictive

Supports Sensitivity Response

accepted

EID4858

In a randomized, open-label phase 3 trial 303 patients with ALK-positive, previously untreated NSCLC (including asympt. CNS disease) were randomized to reiceive either Alectinib or Crizotinib. During … (full text at CIViC)

PMID 28586279 · Peters et al., 2017 ·

Malignant Breast Neoplasm1
v::ALK Fusion	Crizotinib	Predictive	E	Supports Sensitivity Response	1	accepted	EID1335 84 breast cancer samples acquired from commercial sources were assayed on Affymetrix human exon 1.0 arrays. A computational method was used to find potential gene fusions which assessed differential e… (full text at CIViC) PMID 19737969 · Lin et al., 2009 · Open in CIViC	civic

Malignant Breast Neoplasm1

v::ALK Fusion

Crizotinib

Predictive

Supports Sensitivity Response

accepted

EID1335

84 breast cancer samples acquired from commercial sources were assayed on Affymetrix human exon 1.0 arrays. A computational method was used to find potential gene fusions which assessed differential e… (full text at CIViC)

PMID 19737969 · Lin et al., 2009 · Open in CIViC

civic

Malignant Neoplasm5
ALK G1269A AND v::ALK Fusion	Alectinib	Predictive	D	Supports Resistance	3	accepted	EID1354 EML4-ALK with ALK G1269A mutation was tested for sensitivity to alectinib using Ba/F3 cells. In Ba/F3 cells with ectopic EML4-ALK variant 1 G1269A, IC50 of 84 nM was reported with alectinib, which was… (full text at CIViC) PMID 25727400 · Fontana et al., 2015 · Open in CIViC	civic
ALK G1269A AND v::ALK Fusion	Brigatinib	Predictive	D	Supports Sensitivity Response	2	accepted	EID1353 EML4-ALK with ALK G1269A has been seen in crizotinib resistant NSCLC, and this mutation was tested for Brigatinib sensitivity via ectopic expression in Ba/F3 cells, where half maximal inhibitory conce… (full text at CIViC) PMID 25727400 · Fontana et al., 2015 · Open in CIViC	civic
ALK G1269A AND v::ALK Fusion	Ceritinib	Predictive	D	Supports Sensitivity Response	2	accepted	EID1355 EML4-ALK with G1269A mutation was tested for sensitivity to ceritinib via transduction into Ba/F3 cells and generation of survival curves varying ceritinib concentration. IC50 of 33 nM was seen, which… (full text at CIViC) PMID 25727400 · Fontana et al., 2015 · Open in CIViC	civic
v::ALK Fusion	Entrectinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID2952 Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the anti… (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC	civic
v::ALK Fusion OR v::ROS1 Fusion	Crizotinib	Predictive	B	Supports Sensitivity Response	2	accepted	EID11671 This clinical study was conducted on patients harboring either ROS1 or ALK rearrangements, and were treated with Crizotinib. The two sub-protocols F(ALK rearrangements) and G(ROS1 rearrangements) had … (full text at CIViC) PMID 35233056 · Mansfield et al., 2022 · Open in CIViC	civic

Malignant Neoplasm5

ALK G1269A AND v::ALK Fusion

Alectinib

Predictive

Supports Resistance

accepted

EID1354

EML4-ALK with ALK G1269A mutation was tested for sensitivity to alectinib using Ba/F3 cells. In Ba/F3 cells with ectopic EML4-ALK variant 1 G1269A, IC50 of 84 nM was reported with alectinib, which was… (full text at CIViC)

PMID 25727400 · Fontana et al., 2015 · Open in CIViC

civic

ALK G1269A AND v::ALK Fusion

Brigatinib

Predictive

Supports Sensitivity Response

accepted

EID1353

EML4-ALK with ALK G1269A has been seen in crizotinib resistant NSCLC, and this mutation was tested for Brigatinib sensitivity via ectopic expression in Ba/F3 cells, where half maximal inhibitory conce… (full text at CIViC)

PMID 25727400 · Fontana et al., 2015 · Open in CIViC

civic

ALK G1269A AND v::ALK Fusion

Ceritinib

Predictive

Supports Sensitivity Response

accepted

EID1355

EML4-ALK with G1269A mutation was tested for sensitivity to ceritinib via transduction into Ba/F3 cells and generation of survival curves varying ceritinib concentration. IC50 of 33 nM was seen, which… (full text at CIViC)

PMID 25727400 · Fontana et al., 2015 · Open in CIViC

civic

v::ALK Fusion

Entrectinib

Predictive

Supports Sensitivity Response

accepted

EID2952

Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the anti… (full text at CIViC)

PMID 28183697 · Drilon et al., 2017 · Open in CIViC

civic

v::ALK Fusion OR v::ROS1 Fusion

Crizotinib

Predictive

Supports Sensitivity Response

accepted

EID11671

This clinical study was conducted on patients harboring either ROS1 or ALK rearrangements, and were treated with Crizotinib. The two sub-protocols F(ALK rearrangements) and G(ROS1 rearrangements) had … (full text at CIViC)

PMID 35233056 · Mansfield et al., 2022 · Open in CIViC

civic

Thyroid Gland Anaplastic Carcinoma1
v::ALK Fusion	Crizotinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID5954 A patient with anaplastic thyroid carcinoma harboring ALK rearrangement received crizotinib after chemotherapy for pulmonary recurrence. Crizotinib showed confirmed response of more than 90% by tumor … (full text at CIViC) PMID 24687827 · Godbert et al., 2015 · Open in CIViC	civic

Thyroid Gland Anaplastic Carcinoma1

v::ALK Fusion

Crizotinib

Predictive

Supports Sensitivity Response

accepted

EID5954

A patient with anaplastic thyroid carcinoma harboring ALK rearrangement received crizotinib after chemotherapy for pulmonary recurrence. Crizotinib showed confirmed response of more than 90% by tumor … (full text at CIViC)

PMID 24687827 · Godbert et al., 2015 · Open in CIViC

civic

Vaginal Sarcoma1
v::ALK Fusion	Crizotinib	Predictive	C	Supports Sensitivity Response	2	accepted	EID6042 Patient was 34-year-old woman with vaginal sarcoma, which was excised with positive surgical margins. Fluorescence in situ hybridization testing of her tumor revealed anaplastic lymphoma kinase gene … (full text at CIViC) PMID 26942346 · Forde et al., 2016 · Open in CIViC	civic

Vaginal Sarcoma1

v::ALK Fusion

Crizotinib

Predictive

Supports Sensitivity Response

accepted

EID6042

Patient was 34-year-old woman with vaginal sarcoma, which was excised with positive surgical margins. Fluorescence in situ hybridization testing of her tumor revealed anaplastic lymphoma kinase gene … (full text at CIViC)

PMID 26942346 · Forde et al., 2016 · Open in CIViC

civic

Epithelioid Inflammatory Myofibroblastic Sarcoma1unmapped disease
v::ALK Fusion	Crizotinib	Predictive	C	Supports Sensitivity Response	2	accepted	EID6043 This is a case report of a 22-year-old Japanese man with a pelvic mesenchymal neoplasm. Tumor analysis include IHC and RT-PCR led to diagnosis of epithelioid inflammatory myofibroblastic sarcoma with… (full text at CIViC) PMID 25028698 · Kimbara et al., 2014 · Open in CIViC	civic

Epithelioid Inflammatory Myofibroblastic Sarcoma1unmapped disease

v::ALK Fusion

Crizotinib

Predictive

Supports Sensitivity Response

accepted

EID6043

This is a case report of a 22-year-old Japanese man with a pelvic mesenchymal neoplasm. Tumor analysis include IHC and RT-PCR led to diagnosis of epithelioid inflammatory myofibroblastic sarcoma with… (full text at CIViC)

PMID 25028698 · Kimbara et al., 2014 · Open in CIViC

civic

Gastrointestinal Carcinoma1unmapped disease
v::ALK Fusion	Alectinib + Crizotinib + EntrectinibSubstitutes	Predictive	C	Supports Sensitivity Response	3	submitted	EID10324 Retrospective analysis of patients with ALK-fusion positive gastrointestinal cancers. 13 patients were identified (5 pancreas, 3 right-sided colon, 1 gastric, 1 duodenal, 1 rectal, 1 left-sided colon,… (full text at CIViC) PMID 35476549 · Ambrosini et al., 2022 · Open in CIViC	civic

Gastrointestinal Carcinoma1unmapped disease

v::ALK Fusion

Alectinib + Crizotinib + EntrectinibSubstitutes

Predictive

Supports Sensitivity Response

submitted

EID10324

Retrospective analysis of patients with ALK-fusion positive gastrointestinal cancers. 13 patients were identified (5 pancreas, 3 right-sided colon, 1 gastric, 1 duodenal, 1 rectal, 1 left-sided colon,… (full text at CIViC)

PMID 35476549 · Ambrosini et al., 2022 · Open in CIViC

civic

Evidence by cancer (71 items)

Clinical significance (0)